Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carmustine + ifosfamide is a combination of two alkylating chemotherapeutic agents used together in oncology regimens for the treatment of various malignancies. Carmustine (a nitrosourea) and ifosfamide (an oxazaphosphorine) both act by alkylating DNA, leading to cross-linking and inhibition of DNA replication and transcription, ultimately resulting in cell death. This combination may be used as part of high-dose chemotherapy protocols or salvage regimens for cancers such as lymphomas, brain tumors, sarcomas, and other solid tumors. Each drug has a distinct toxicity profile; carmustine is notable for pulmonary toxicity and delayed myelosuppression, while ifosfamide can cause hemorrhagic cystitis and neurotoxicity. The rationale for combining these agents lies in their different mechanisms within the alkylator class and non-overlapping toxicities.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carmustine + ifosfamide.